About anixa biosciences - ANIX
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
ANIX At a Glance
Anixa Biosciences, Inc.
3150 Almaden Expressway
San Jose, California 95118
| Phone | 1-408-708-9808 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -10,927,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 10 / 2026 | |||
| View SEC Filings |
ANIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.993 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.103 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
ANIX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,731,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANIX Liquidity
| Current Ratio | 8.077 |
| Quick Ratio | 8.077 |
| Cash Ratio | 7.714 |
ANIX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -58.013 |
| Return on Equity | -62.158 |
| Return on Total Capital | -71.116 |
| Return on Invested Capital | -61.517 |
ANIX Capital Structure
| Total Debt to Total Equity | 1.346 |
| Total Debt to Total Capital | 1.328 |
| Total Debt to Total Assets | 1.269 |
| Long-Term Debt to Equity | 1.075 |
| Long-Term Debt to Total Capital | 1.061 |
Anixa Biosciences in the News
Breast cancer vaccine could prevent most aggressive form of disease from reoccurring
Scientists are currently testing a vaccine that could prevent the reoccurrence of triple-negative breast cancer, the most aggressive form of the disease.